Selected research
Industry Research
Nucleic Vaccine Industry Research Report 2026
Market perspective
The global Nucleic Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Nucleic Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Nucleic Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Nucleic Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Nucleic Vaccine include CNBG, Zhifei Shengwu, Walvax Biotechnology, Sanofi, Liaoning Chengda, CanSinoBIO, BioKangtai, Hualan Bio and GSK, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Nucleic Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nucleic Vaccine Market by Company
CNBG
Zhifei Shengwu
Walvax Biotechnology
Sanofi
Liaoning Chengda
CanSinoBIO
BioKangtai
Hualan Bio
GSK
Fosun Pharma
Moderna
Inovio
CureVac
Nucleic Vaccine Segment by Type
Preventive Nucleic Vaccine
Therapeutic Nucleic Vaccine
Nucleic Vaccine Segment by Application
Hospital
Clinic
Others
Nucleic Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nucleic Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nucleic Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nucleic Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Nucleic Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Nucleic Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Nucleic Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Preventive Nucleic Vaccine
- Therapeutic Nucleic Vaccine
Applications
- Hospital
- Clinic
- Others
Companies covered
- CNBG
- Zhifei Shengwu
- Walvax Biotechnology
- Sanofi
- Liaoning Chengda
- CanSinoBIO
- BioKangtai
- Hualan Bio
- GSK
- Fosun Pharma
- Moderna
- Inovio
- CureVac
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Nucleic Vaccine Market Size (2021-2032)
- 2.2.2 Global Nucleic Vaccine Sales (2021-2032)
- 2.2.3 Global Nucleic Vaccine Market Average Price (2021-2032)
- 2.3 Nucleic Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Preventive Nucleic Vaccine
- 2.3.3 Therapeutic Nucleic Vaccine
- 2.4 Nucleic Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Nucleic Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Nucleic Vaccine Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Nucleic Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Nucleic Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Nucleic Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Nucleic Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Nucleic Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Nucleic Vaccine, Established Date
- 3.9 Global Nucleic Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CNBG
- 4.1.1 CNBG Company Information
- 4.1.2 CNBG Business Overview
- 4.1.3 CNBG Nucleic Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CNBG Nucleic Vaccine Product Portfolio
- 4.1.5 CNBG Recent Developments
- 4.2 Zhifei Shengwu
- 4.2.1 Zhifei Shengwu Company Information
- 4.2.2 Zhifei Shengwu Business Overview
- 4.2.3 Zhifei Shengwu Nucleic Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Zhifei Shengwu Nucleic Vaccine Product Portfolio
- 4.2.5 Zhifei Shengwu Recent Developments
- 4.3 Walvax Biotechnology
- 4.3.1 Walvax Biotechnology Company Information
- 4.3.2 Walvax Biotechnology Business Overview
- 4.3.3 Walvax Biotechnology Nucleic Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Walvax Biotechnology Nucleic Vaccine Product Portfolio
- 4.3.5 Walvax Biotechnology Recent Developments
- 4.4 Sanofi
- 4.4.1 Sanofi Company Information
- 4.4.2 Sanofi Business Overview
- 4.4.3 Sanofi Nucleic Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sanofi Nucleic Vaccine Product Portfolio
- 4.4.5 Sanofi Recent Developments
- 4.5 Liaoning Chengda
- 4.5.1 Liaoning Chengda Company Information
- 4.5.2 Liaoning Chengda Business Overview
- 4.5.3 Liaoning Chengda Nucleic Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Liaoning Chengda Nucleic Vaccine Product Portfolio
- 4.5.5 Liaoning Chengda Recent Developments
- 4.6 CanSinoBIO
- 4.6.1 CanSinoBIO Company Information
- 4.6.2 CanSinoBIO Business Overview
- 4.6.3 CanSinoBIO Nucleic Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 CanSinoBIO Nucleic Vaccine Product Portfolio
- 4.6.5 CanSinoBIO Recent Developments
- 4.7 BioKangtai
- 4.7.1 BioKangtai Company Information
- 4.7.2 BioKangtai Business Overview
- 4.7.3 BioKangtai Nucleic Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 BioKangtai Nucleic Vaccine Product Portfolio
- 4.7.5 BioKangtai Recent Developments
- 4.8 Hualan Bio
- 4.8.1 Hualan Bio Company Information
- 4.8.2 Hualan Bio Business Overview
- 4.8.3 Hualan Bio Nucleic Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Hualan Bio Nucleic Vaccine Product Portfolio
- 4.8.5 Hualan Bio Recent Developments
- 4.9 GSK
- 4.9.1 GSK Company Information
- 4.9.2 GSK Business Overview
- 4.9.3 GSK Nucleic Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 GSK Nucleic Vaccine Product Portfolio
- 4.9.5 GSK Recent Developments
- 4.10 Fosun Pharma
- 4.10.1 Fosun Pharma Company Information
- 4.10.2 Fosun Pharma Business Overview
- 4.10.3 Fosun Pharma Nucleic Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Fosun Pharma Nucleic Vaccine Product Portfolio
- 4.10.5 Fosun Pharma Recent Developments
- 4.11 Moderna
- 4.11.1 Moderna Company Information
- 4.11.2 Moderna Business Overview
- 4.11.3 Moderna Nucleic Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Moderna Nucleic Vaccine Product Portfolio
- 4.11.5 Moderna Recent Developments
- 4.12 Inovio
- 4.12.1 Inovio Company Information
- 4.12.2 Inovio Business Overview
- 4.12.3 Inovio Nucleic Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Inovio Nucleic Vaccine Product Portfolio
- 4.12.5 Inovio Recent Developments
- 4.13 CureVac
- 4.13.1 CureVac Company Information
- 4.13.2 CureVac Business Overview
- 4.13.3 CureVac Nucleic Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 CureVac Nucleic Vaccine Product Portfolio
- 4.13.5 CureVac Recent Developments
5 Global Nucleic Vaccine Market Scenario by Region
- 5.1 Global Nucleic Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Nucleic Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Nucleic Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Nucleic Vaccine Sales by Region: 2027-2032
- 5.3 Global Nucleic Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Nucleic Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Nucleic Vaccine Revenue by Region: 2027-2032
- 5.4 North America Nucleic Vaccine Market Facts & Figures by Country
- 5.4.1 North America Nucleic Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Nucleic Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Nucleic Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Nucleic Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Nucleic Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Nucleic Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Nucleic Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Nucleic Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Nucleic Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Nucleic Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Nucleic Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Nucleic Vaccine Market Facts & Figures by Country
- 5.7.1 South America Nucleic Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Nucleic Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Nucleic Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Nucleic Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Nucleic Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Nucleic Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Nucleic Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Nucleic Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Nucleic Vaccine Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Nucleic Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Nucleic Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Nucleic Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Nucleic Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Nucleic Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Nucleic Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Nucleic Vaccine Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Nucleic Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Nucleic Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Nucleic Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Nucleic Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Nucleic Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Nucleic Vaccine Value Chain Analysis
- 8.1.1 Nucleic Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Nucleic Vaccine Production Mode & Process
- 8.2 Nucleic Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Nucleic Vaccine Distributors
- 8.2.3 Nucleic Vaccine Customers
9 Global Nucleic Vaccine Analyzing Market Dynamics
- 9.1 Nucleic Vaccine Industry Trends
- 9.2 Nucleic Vaccine Industry Drivers
- 9.3 Nucleic Vaccine Industry Opportunities and Challenges
- 9.4 Nucleic Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst